{"title":"抗氧化剂在降低抗药性癫痫患者氧化应激和癫痫发作频率方面的作用。","authors":"Jufitriani Ismy, Amanda Soebadi, Irawan Mangunatmadja, Merci Monica, Teny T Sari, Klara Yuliarti","doi":"10.52225/narra.v4i2.790","DOIUrl":null,"url":null,"abstract":"<p><p>Drug-resistant epilepsy presents significant challenges in treating epileptic patients, leading to recurrent seizures and necessitating the use of polypharmacy with anti-epileptic drugs. Both of these conditions contribute to increased oxidative stress, which is detrimental to the brain. The aim of this study was to determine the role of vitamins C and E in reducing oxidative stress and seizure frequency in drug-resistant epileptic patients. This was a double-blinded, randomized clinical trial with a placebo, parallel design, and block randomization. The subjects were drug-resistant epileptic patients aged 1-18 years who received routine treatment. Randomization was performed on 100 patients who were divided into the treatment or placebo groups. The patients received a combination of vitamin C (100 mg/day) and vitamin E (200 IU/day for those <5 years or 400 IU/day for those ≥5 years) or a placebo for eight weeks. Malondialdehyde (MDA) levels and seizure frequency were measured prior to and after the intervention. A total of 42 and 46 patients were followed till the end of the study in the intervention and placebo groups, respectively. Our data indicated that the MDA levels prior to treatment were not significantly different between the treatment and placebo groups (0.901 vs 0.890 mmol/mL, <i>p</i>=0.920) and were significantly reduced after the treatment in both the treatment group (<i>p</i><0.001) and placebo group (<i>p</i>=0.028). The changes in MDA levels (between post- and pre-treatment) were also not significantly different between the two groups (<i>p</i>=0.181). Our per-protocol analysis indicated that the reduction in seizure frequency was significantly higher in the treatment group compared to the placebo group (95% vs 35%, <i>p</i><0.001), with 92% and 60% relative and absolute risk reduction, respectively. The intention-to-treat analysis also indicated that the reduction in seizure frequency was significantly higher in the intervention group than in the control group (80% vs 32%, <i>p</i><0.001), with relative and absolute risk reduction of 70% and 48%, respectively. There was no significant relationship between changes in MDA levels and seizure frequency in either group. In conclusion, vitamins C and E could reduce seizure frequency and, therefore, could be considered as adjuvant therapy in drug-resistant epileptic patients.</p>","PeriodicalId":517416,"journal":{"name":"Narra J","volume":"4 2","pages":"e790"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11391982/pdf/","citationCount":"0","resultStr":"{\"title\":\"Role of antioxidants in reducing oxidative stress and seizure frequency in drug-resistant epileptic patients.\",\"authors\":\"Jufitriani Ismy, Amanda Soebadi, Irawan Mangunatmadja, Merci Monica, Teny T Sari, Klara Yuliarti\",\"doi\":\"10.52225/narra.v4i2.790\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Drug-resistant epilepsy presents significant challenges in treating epileptic patients, leading to recurrent seizures and necessitating the use of polypharmacy with anti-epileptic drugs. Both of these conditions contribute to increased oxidative stress, which is detrimental to the brain. The aim of this study was to determine the role of vitamins C and E in reducing oxidative stress and seizure frequency in drug-resistant epileptic patients. This was a double-blinded, randomized clinical trial with a placebo, parallel design, and block randomization. The subjects were drug-resistant epileptic patients aged 1-18 years who received routine treatment. Randomization was performed on 100 patients who were divided into the treatment or placebo groups. The patients received a combination of vitamin C (100 mg/day) and vitamin E (200 IU/day for those <5 years or 400 IU/day for those ≥5 years) or a placebo for eight weeks. Malondialdehyde (MDA) levels and seizure frequency were measured prior to and after the intervention. A total of 42 and 46 patients were followed till the end of the study in the intervention and placebo groups, respectively. Our data indicated that the MDA levels prior to treatment were not significantly different between the treatment and placebo groups (0.901 vs 0.890 mmol/mL, <i>p</i>=0.920) and were significantly reduced after the treatment in both the treatment group (<i>p</i><0.001) and placebo group (<i>p</i>=0.028). The changes in MDA levels (between post- and pre-treatment) were also not significantly different between the two groups (<i>p</i>=0.181). Our per-protocol analysis indicated that the reduction in seizure frequency was significantly higher in the treatment group compared to the placebo group (95% vs 35%, <i>p</i><0.001), with 92% and 60% relative and absolute risk reduction, respectively. The intention-to-treat analysis also indicated that the reduction in seizure frequency was significantly higher in the intervention group than in the control group (80% vs 32%, <i>p</i><0.001), with relative and absolute risk reduction of 70% and 48%, respectively. There was no significant relationship between changes in MDA levels and seizure frequency in either group. In conclusion, vitamins C and E could reduce seizure frequency and, therefore, could be considered as adjuvant therapy in drug-resistant epileptic patients.</p>\",\"PeriodicalId\":517416,\"journal\":{\"name\":\"Narra J\",\"volume\":\"4 2\",\"pages\":\"e790\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11391982/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Narra J\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.52225/narra.v4i2.790\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/19 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Narra J","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52225/narra.v4i2.790","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/19 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
耐药性癫痫给癫痫患者的治疗带来了巨大挑战,它导致癫痫反复发作,使患者不得不使用多种抗癫痫药物。这两种情况都会导致氧化应激增加,从而对大脑造成损害。本研究旨在确定维生素 C 和 E 在降低抗药性癫痫患者氧化应激和癫痫发作频率方面的作用。这是一项双盲、随机临床试验,采用安慰剂、平行设计和分块随机法。受试者为接受常规治疗的 1-18 岁耐药性癫痫患者。100 名患者被随机分为治疗组和安慰剂组。患者接受维生素 C(100 毫克/天)和维生素 E(200 IU/天,P=0.920)联合治疗,治疗后两组患者的 MDA 水平均显著降低(pp=0.028)。两组之间的 MDA 水平变化(治疗后与治疗前)也无明显差异(P=0.181)。我们的协议分析表明,治疗组的癫痫发作频率减少率明显高于安慰剂组(95% vs 35%,pp=0.028)。
Role of antioxidants in reducing oxidative stress and seizure frequency in drug-resistant epileptic patients.
Drug-resistant epilepsy presents significant challenges in treating epileptic patients, leading to recurrent seizures and necessitating the use of polypharmacy with anti-epileptic drugs. Both of these conditions contribute to increased oxidative stress, which is detrimental to the brain. The aim of this study was to determine the role of vitamins C and E in reducing oxidative stress and seizure frequency in drug-resistant epileptic patients. This was a double-blinded, randomized clinical trial with a placebo, parallel design, and block randomization. The subjects were drug-resistant epileptic patients aged 1-18 years who received routine treatment. Randomization was performed on 100 patients who were divided into the treatment or placebo groups. The patients received a combination of vitamin C (100 mg/day) and vitamin E (200 IU/day for those <5 years or 400 IU/day for those ≥5 years) or a placebo for eight weeks. Malondialdehyde (MDA) levels and seizure frequency were measured prior to and after the intervention. A total of 42 and 46 patients were followed till the end of the study in the intervention and placebo groups, respectively. Our data indicated that the MDA levels prior to treatment were not significantly different between the treatment and placebo groups (0.901 vs 0.890 mmol/mL, p=0.920) and were significantly reduced after the treatment in both the treatment group (p<0.001) and placebo group (p=0.028). The changes in MDA levels (between post- and pre-treatment) were also not significantly different between the two groups (p=0.181). Our per-protocol analysis indicated that the reduction in seizure frequency was significantly higher in the treatment group compared to the placebo group (95% vs 35%, p<0.001), with 92% and 60% relative and absolute risk reduction, respectively. The intention-to-treat analysis also indicated that the reduction in seizure frequency was significantly higher in the intervention group than in the control group (80% vs 32%, p<0.001), with relative and absolute risk reduction of 70% and 48%, respectively. There was no significant relationship between changes in MDA levels and seizure frequency in either group. In conclusion, vitamins C and E could reduce seizure frequency and, therefore, could be considered as adjuvant therapy in drug-resistant epileptic patients.